CBC Group Acquires UCB's Mature Neuroscience Portfolio in China to Enhance Patient Care

CBC Group Strengthens its Position with Acquisition of UCB's Product Portfolio in China

CBC Group, established as Asia's largest healthcare-focused asset management firm, has made headlines with the acquisition of a significant portfolio from the global biopharmaceutical giant, UCB. This strategic maneuver was officially announced on November 30, 2024, and comes as part of CBC’s ambitious buyout strategy aimed at enhancing patient care and expanding its presence in the dynamic Chinese pharmaceutical market.

The deal, valued at $680 million, includes UCB's mature products in the domains of neurology and allergy, notably featuring well-known medications such as Keppra®, Vimpat®, Neupro®, Zyrtec®, and Xyzal®. This substantial investment not only underscores the growing significance of the CNS (Central Nervous System) therapeutics market, which has recently reached a staggering size of $33 billion in China, but also marks a pivotal shift in CBC's operational approach in the rapidly evolving healthcare landscape.

An Integrated Approach

CBC Group’s acquisition strategy has been carefully orchestrated to target key assets from renowned global pharmaceutical companies, and this latest acquisition underscores their commitment to building an integrated biopharmaceutical platform within China. By forming the new company, NeuroGen Pharma, CBC and its partner Mubadala Investment Company—based in Abu Dhabi—aim to pioneer innovations in neurology care, leveraging their combined expertise and strong track record in the biopharma industry.

The operational leadership of NeuroGen Pharma will be headed by a management team with extensive experience in the biopharmaceutical sector, ensuring a seamless transition and effective execution of the company’s growth strategy.

Meeting the Demand for Neurology Treatments

The expansion into the Chinese market comes at a crucial time as there is an increasing demand for effective treatments in neurology and allergy sectors. Fu Wei, the Chief Executive Officer of CBC Group, emphasized the vast potential within the healthcare market to enhance patient care for individuals with unmet medical needs. By harnessing their